An infant brought to the hospital with chief complaints of distended abdomen and short stature .on examination liver and kidneys were enlarged.laboratory finding shows low plasma glucose,uric acid-10%,serum cholesterol -278mg% What is the probable diagnosis

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
I now have excellent textbook material. Here is the complete answer:

Probable Diagnosis: Von Gierke Disease (Glycogen Storage Disease Type I)

This presentation is classic for GSD Type Ia (Von Gierke disease) - caused by a deficiency of the enzyme glucose-6-phosphatase.

Matching the Clinical Features

Finding in the CaseExplanation in Von Gierke Disease
Distended abdomenMassive hepatomegaly from glycogen accumulation in the liver
Short statureGrowth retardation - a hallmark feature
Enlarged liverPrimary site of glycogen storage
Enlarged kidneysGlycogen also deposits in renal tubular cells causing nephromegaly
Low plasma glucoseGlucose-6-phosphatase is needed for the final step of both glycogenolysis and gluconeogenesis; its absence causes severe fasting hypoglycemia
Uric acid elevated (10%)Hyperuricemia - caused by competitive inhibition by lactate of renal tubular urate secretion, plus increased uric acid production
Serum cholesterol 278 mg%Hyperlipidemia - from increased lipolysis secondary to decreased glucose availability, causing hypertriglyceridemia and hypercholesterolemia

Pathophysiology

Glucose-6-phosphatase catalyzes the last step of both gluconeogenesis and glycogenolysis in the liver:
Glucose-6-phosphate → Glucose (requires glucose-6-phosphatase)
Without this enzyme:
  • Glycogen cannot be converted to free glucose → hypoglycemia
  • Glucose-6-phosphate builds up → excess glycolysis → lactic acidosis
  • Lactate competes with urate for renal tubular secretion → hyperuricemia
  • Hypoglycemia stimulates lipolysis → hyperlipidemia (high cholesterol + triglycerides)
  • Glycogen accumulates in hepatocytes and renal tubular cells → hepato-nephromegaly

Inheritance and Subtypes

  • Autosomal recessive inheritance
  • Type Ia (~80%): defect in glucose-6-phosphatase catalytic subunit (G6PC gene)
  • Type Ib (~20%): defect in the glucose-6-phosphate translocase (transport system)

Key Diagnostic Tests

  1. Failure to raise blood glucose after galactose loading (galactose is normally converted to glucose via glucose-6-phosphate, but this last step is blocked)
  2. Epinephrine/glucagon tolerance test: no rise in blood glucose (but lactate rises instead)
  3. Liver biopsy with direct assay of glucose-6-phosphatase activity - confirmatory
  4. Genetic testing for G6PC mutations

Treatment

  • Frequent meals and nocturnal nasogastric feeding with uncooked cornstarch to maintain blood glucose
  • Avoidance of prolonged fasting
  • Allopurinol for hyperuricemia
  • Dietary management of hyperlipidemia

Sources: Tietz Textbook of Laboratory Medicine, 7th ed.; Robbins & Kumar Basic Pathology; Lippincott Illustrated Reviews Biochemistry, 8th ed.
analyse_media
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have all the textbook data needed for all 4 cases. Here is the complete answer:

All 4 Clinical Cases - Glycogen Storage Diseases (GSD)


Clinical Case 1 - ✅ Already Discussed

Diagnosis: Von Gierke Disease (GSD Type Ia)
  • Deficient enzyme: Glucose-6-phosphatase
  • Key features: Hepato-nephromegaly, short stature, hypoglycemia, hyperuricemia, hypercholesterolemia

Clinical Case 2

Diagnosis: Pompe Disease (GSD Type II)
  • Deficient enzyme: Acid α-glucosidase (Acid maltase)
Feature in CaseExplanation
Neonate with hepatomegalyGlycogen accumulates in liver
Cardiac hypertrophy on echoMassive glycogen deposition in cardiac muscle - cardiomegaly is the dominant feature
Floppy baby, diminished muscle toneSkeletal muscle glycogen accumulation → muscle weakness
Low α-glucosidase in leukocytes, muscle, liverConfirms the enzyme deficiency (diagnostic)
  • This is the infantile form - presents in first few months of life, patients usually die within 1 year from cardiac failure
  • It is the only GSD that is also a lysosomal storage disease (the enzyme is lysosomal)
  • Blood glucose is normal (unlike Von Gierke) since glucose-6-phosphatase is intact
  • Treatment: Enzyme replacement therapy with recombinant human acid α-glucosidase (approved 2006)

Clinical Case 3

Diagnosis: McArdle Disease (GSD Type V)
  • Deficient enzyme: Muscle glycogen phosphorylase (myophosphorylase)
Feature in CaseExplanation
Fatigability worsened on exertionMuscle cannot break down glycogen for energy during exercise
Lags behind friends on walkingExercise intolerance - typical presentation in young adults
Muscle biopsy: subsarcolemmal "lakes" of glycogenPathognomonic - glycogen accumulates just beneath the muscle cell membrane
  • Characteristic sign: "Second wind phenomenon" - symptoms improve after ~10 min of moderate exercise as fatty acid metabolism kicks in
  • Forearm ischemic test: flat venous lactate curve with exaggerated ammonia rise (because the glycolytic block prevents lactate production)
  • Serum CK is elevated even at rest
  • No cardiac or liver involvement
  • Blood glucose and lactate are low after exercise (as seen in Case 4, which is the same disease)

Clinical Case 4 - ✅ Answered in Notes

Diagnosis: McArdle Disease (GSD Type V)
  • Deficient enzyme: Muscle glycogen phosphorylase
  • Post-exercise: low plasma glucose + low lactate + high muscle glycogen = classic McArdle picture
  • The glycolytic block means lactate cannot be produced from muscle glycogen

Quick Reference Summary Table

CaseDiseaseGSD TypeDeficient EnzymeKey Clue
1Von GierkeType IGlucose-6-phosphataseHepato-nephromegaly + hypoglycemia + hyperuricemia
2PompeType IIAcid α-glucosidaseFloppy neonate + cardiomegaly + normal glucose
3 & 4McArdleType VMuscle glycogen phosphorylaseExercise intolerance + subsarcolemmal glycogen + flat lactate on ischemic test
Sources: Tietz Textbook of Laboratory Medicine 7th ed.; Robbins & Kumar Basic Pathology; Lippincott Biochemistry 8th ed.; Rheumatology 2022 Elsevier
This is a shared conversation. Sign in to Orris to start your own chat.